Clearance Prediction
Be Careful What You Ask for: Challenges of Predicting Human Clearance for a Low Metabolic Turnover Compound, ELND006
Kevin Quinn, Elan Pharmaceuticals;
David Nakamura, Elan Pharmaceuticals;
Heather Zhang, Elan Pharmaceuticals;
Shawn Gauby, Elan Pharmaceuticals;
Colin Lorentzen, Elan Pharmaceuticals;
Erich Goldbach, Elan Pharmaceuticals;
Amanda Moore, Hepregen Corporation;
Salman Khetani, Hepregen Corporation;
Earvin Liang, Elan Pharmaceuticals;
John-Michael Sauer, Elan Pharmaceuticals;
George Tonn, Elan Pharmaceuticals
Prediction of PK parameters of human using human chimeric mice
Seigo Sanoh, Hiroshima University;
Aya Horiguchi, Hiroshima University;
Kazumi Sugihara, Hiroshima International University;
Chise Tateno, PhoenixBio Co., Ltd.;
Toru Horie, De Three Reseach Laboratories;
Shigeyuki Kitamura, Nihon Pharmaceutical University;
Shigeru Ohta, Hiroshima University
UTILIZATION OF CHIMERIC MICE WITH HUMANIZED LIVER AS A USEFUL MODEL FOR PREDICTING HUMAN PHARMACOKINETICS (PK) OF A DRUG CANDIDATE WITH MAJOR ALDEHYDE OXIDASE (AO) METABOLISM
Maria D. Bacolod, Lundbeck Research USA, Inc.;
Kimloan Nguyen, Lundbeck Research USA, Inc.;
Zack Zou, Lundbeck Research USA, Inc.;
Guiying Li, Lundbeck Research USA, Inc.;
Hao Zhou, Lundbeck Research USA, Inc.;
Dario Doller, Lundbeck Research USA, Inc.;
Gamini Chandrasena, Lundbeck Research USA, Inc.
![[ Visit Client Website ]](images/banner.gif)